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1  | INTRODUC TION
Glioblastoma (GBM) is the most common and lethal primary brain 
tumour.1,2 GBM is classified as Grade IV glioma by the World Health 
Organization, and patients have a median survival of approximately 
14.6 months post‐diagnosis.3 Recently, tumour classification is 
shifting towards utilizing gene indices and molecular correlates. This 
allows for more precise treatments tailored to patient‐specific tu‐
mour subtypes. Combination of therapeutics precisely designed to 
target these individual subsets of GBM are increasingly becoming 
the basis of current day anti‐GBM therapies. Mining of databases 
comprising of genome and proteome changes in GBM patients 
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Glioblastoma (GBM) is the most frequent and inevitably lethal primary brain cancer in 
adults. It is recognized that the overexpression of the endosomal Na+/H+ exchanger 
NHE9	 is	a	potent	driver	of	GBM	progression.	Patients	with	NHE9	overexpression	
have a threefold lower median survival relative to GBM patients with normal NHE9 
expression, using available treatment options. New treatment strategies tailored for 
this	GBM	subset	are	much	needed.	According	to	the	prevailing	model,	NHE9	overex‐




we report that this gain of function in NHE9 can be exploited to effectively target 
GBM cells for destruction. When exposed to gold nanoparticles, NHE9 overexpress‐
ing GBM cells accumulated drastically high amounts of gold via receptor‐mediated 
endocytosis, relative to control. Irradiation of these cells with near‐infrared light led 
to	apoptotic	tumour	cell	death.	A	major	limitation	for	delivering	therapeutics	to	GBM	
cells is the blood‐brain barrier (BBB). Here, we demonstrate that macrophages loaded 
with gold nanoparticles can cross the BBB, deliver the gold nanoparticles and effect 
the demise of GBM cells. In combination with receptor tyrosine kinase inhibition, we 
show this approach holds great promise for a new GBM‐targeted therapy.
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led to discovery of a subset of GBM associated with NHE9 over‐
expression.4 Notably, tumours in this subset are non‐responsive to 
radiation and chemotherapy. NHE9 up‐regulation correlated with 
significantly shorter disease‐free periods post‐tumour resection and 
decreased patient survival.4
NHE9 is a sodium (potassium) proton antiporter encoded by the 
gene	SLC9A9.	NHE9	 is	 localized	mostly	 to	early	 and	 recycling	en‐
dosomes in glia, where it transports the protons out of the endoso‐
mal lumen in exchange for sodium or potassium ions, alkalizing the 
endosomal lumen in this process.5,6 NHE9 is one of the top 12% of 
overexpressed genes in GBM.4 Mechanistic interrogation of patient‐
derived glioblastomas indicated NHE9 overexpression led to an  in‐
creased	 number	 of	 epidermal	 growth	 factor	 receptors	 (EGFRs)	 on	
the cell surface.4	In	normal	glia,	EGFRs	are	endocytosed	and	routed	
for lysosomal degradation, after triggering downstream signalling 
cascades for cell growth and proliferation.7 However, NHE9 over‐
expression	limits	luminal	acidification	to	route	endocytosed	EGFRs	
to the plasma membrane instead of the lysosomes.4 Thus, NHE9 
up‐regulation	exerts	post‐translational	control	over	EGFR	turnover,	
resulting in the persistence of oncogenic signalling pathways that 
drive tumour growth.4 We recently identified down‐regulation of 
microRNA‐135a	as	a	potential	mechanism	underlying	the	high	NHE9	
expression observed in the GBM subset.8
Clinical	 trials	using	drugs	 targeting	EGFR	kinases	have	not	had	
very successful outcomes due to various factors including adapta‐
tion to dose‐limiting drug toxicity.9 NHE9 overexpression in glioblas‐
toma cells was shown to greatly decrease the efficacy of erlotinib, a 
known	FDA‐approved	tyrosine	kinase	inhibitor	of	EGFR.4 The goal of 
this study was to integrate the knowledge gained from our previous 
investigations into NHE9 function, to significantly improve the effi‐
cacy in the treatment of the subset of GBM associated with NHE9 
overexpression (henceforth referred to as GBM9+). The effects of 
endosomal alkalization due to NHE9 up‐regulation in tumour cells 
are	 not	 restricted	 to	 EGFRs.	 Endosomal	 NHE9	 activity	 exerts	 a	
profound pan‐specific effect on membrane persistence of multiple 
receptors and transporters, and an overall elevation in endocytic 
uptake.4,5,10 Here, we describe a new therapeutic approach that uti‐
lizes this gained function by GBM9+ tumour cells to effectively tar‐
get them for destruction. Gold nanoparticle‐enabled photothermal 
therapy	(NEPTT)	is	gaining	much	interest	as	a	powerful	strategy	for	
cancer treatment.11	Gold	nanoparticles	 (GNPs)	usually	consist	of	a	
dielectric silica core and a thin gold shell.12	GNPs	have	been	shown	
to accumulate in tumour cells mostly via endocytic pathways.13 
When	 irradiated	 with	 near‐infrared	 (NIR)	 light,	 GNPs	 convert	 the	
absorbed light into heat, which is detrimental to the cells accumu‐
lating these particles.13 NIR has the advantage of penetrating deeply 
through healthy tissue without affecting it.12,13
In this study, we demonstrate that NHE9 overexpression results 
in	 strong	elevation	of	GNP	accumulation	 in	 tumour	cells	 and	con‐
sequently	 increased	 susceptibility	 to	NEPTT	 treatment.	 In	 combi‐
nation	with	NEPTT,	erlotinib	can	be	used	at	a	much	 lower	dosage	
in	GBM9+	tumours,	greatly	increasing	the	efficacy	of	the	drug.	An	
important limiting factor for brain cancer therapy is the blood‐brain 
barrier (BBB). Tightly connected brain microvascular endothelial cells 
(BMVECs) of the barrier limit passage of most molecules. However, 
circulating macrophages known to traverse the BBB are frequently 
found in GBMs both in animal studies and patient biopsies.14	Using	
an in vitro model of the BBB, we successfully demonstrated deliv‐
ery	of	GNPs	loaded	in	macrophages	to	GBM9+	tumour	cells	located	
across an intact barrier. Given the dismal prognosis of GBM9+ tu‐
mours, our study paves the way for  a new and combinatorial strat‐
egy that is much needed to target this subset of GBM.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and plasmids
Human brain microvascular endothelial cells (hBMVECs) were main‐
tained in M199 media (Invitrogen) supplemented with 10% foetal 
bovine	serum	 (Sigma)	and	5%	antibiotic‐antimycotic	 (10	000	U/mL	
penicillin,	10	000	mg/mL	streptomycin,	Gibco).	U251n	and	U87	were	
cultured in DMEM (Gibco) and supplemented with 10% foetal bo‐
vine	serum	(Sigma)	and	5%	antibiotic‐antimycotic	(Gibco).	RAW264.7	






ecuted lentiviral packaging of the virus.
2.2 | Synthesis of gold nanoparticles with 
silica cores
Gold nanoparticles with silica cores were made with minor modifica‐
tions	(Appendix	S1).12 Briefly, changes included increased five wash 
cycles after silica core synthesis. Refluxing and stirring were carried 
out	for	1.5	hours	to	allow	for	increased	attachment	of	TSPEI	to	SiO2. 
Finally,	formic	acid	was	the	reducing	agent	instead	of	l‐ascorbic acid. 
The bare and gold nanoshell‐coated particles were characterized by 
transmission	electron	microscopy	 (TEM)	and	UV‐Vis	spectroscopy.	
The silica particle concentration was calculated based on the aver‐
age volume of each individual core particle and the total silica vol‐
ume	for	a	given	amount	of	TEOS	(32).	GNPs	represent	gold	nanoshell	
particles with silica cores.
2.3 | Cellular GNP loading and determination of 
GNP concentration inside the cells
U251n,	 U87	 and	 RAW264.7	 cells	were	 grown	 to	 85%	 confluency	
and	 then	 loaded	with	GNPs	at	desired	concentrations	 for	4	hours	
in serum‐free culture media. Cells were then incubated at 37°C for 
30	minutes	in	10	µmol/L	Calcein	Blue	AM	(Thermo	Fisher	Scientific)	
and imaged after three quick washes with phosphate buffered sa‐
line.	Cells	not	loaded	with	GNPs	served	as	control.	The	fluorescent	
intensity of calcein was quantified as mean fluorescent intensity 
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(MFI)	initially	by	flow	cytometry	and	microscopy.	The	fluorescence	
intensity	was	 linearly	 reduced	 as	 the	 dose	 of	GNPs	 increased.	 As	
the results were very similar by both methods, we used microscopy 
as	the	approach	for	relative	quantification.	Absolute	quantification	
was conducted using inductively coupled plasma mass spectrometry 
(ICP‐MS).	For	 ICP‐MS,	GNP‐loaded	cells	were	 lysed	with	mamma‐
lian	 cell	 protein	 extraction	 reagent	 (Thermo	Fisher	 Scientific)	 that	
included protease inhibitor mixture (halt protease inhibitor mixture; 
Thermo	Fisher	Scientific).	Lysates	were	centrifuged	at	13	000	×	g	for	
15 minutes (4°C). The supernatants were dissolved in 2% hydrochlo‐
ric	 acid	 for	2	hours	before	 collecting	data	 (PerkinElmer).	 The	gold	




mRNA	was	 isolated	 from	U251n	 and	 U87	 cells	 using	 the	 RNeasy	
Mini Kit (Qiagen) following manufacturer's instructions with an ad‐
ditional	step	to	remove	DNA	using	DNase	I	(Ambion,	Thermo	fisher	
Scientific).	 High‐Capacity	 RNA‐to‐cDNA	 Kit	 (Applied	 Biosystems)	





were	 Mm99999915_g1	 (GAPDH),	 Mm00626012_m	 (NHE9)	 and	
Hs03003631_g1	 (18s	rRNA).	Cycle	threshold	 (Ct) values were first 
normalized	 to	 endogenous	 controls	 (GAPDH	 and	 18srRNA).	 Fold	
change was calculated as 2−ΔΔCt, where ΔΔCt is the normalized cycle 
threshold value relative to control. Three technical replicates of at 
least three biological replicates were run to account for variance in 
assays.
2.5 | Endosomal pH measurement
Endosomal pH measurements were conducted using our previously 
published protocols.10	 Briefly,	 U251n	 cells	 plated	 in	 fluorodishes	
(World	 Precision	 Instruments)	 were	 placed	 on	 ice	 for	 10	minutes	
and	then	rinsed	with	cold	imaging	buffer	(Live	Cell	Imaging	Solution	
(Thermo	Fisher	Scientific)	with	20	mmol/L	glucose	and	1%	BSA)	to	




images were acquired (excitation 494 nm and emission 518 nm) with 
Lumascope	 620	 (Etaluma).	 Internal	 fluorescence	 was	 quantified	
using	ImageJ	15 software, and average fluorescence intensity was re‐
corded.	NHE9‐mcherry	was	transfected	using	Lipofectamine	2000	
for	expression	in	U251n	cells.	Tfn‐FITC	fluorescence	was	quantified	
only in mcherry‐positive cells. To normalize for total transferrin up‐
take,	pH‐insensitive	 transferrin	 (50	µg/mL	Alexa	Fluor	568‐conju‐
gated	transferrin	 (Tfn‐568)	was	 loaded.	A	pH	calibration	buffer	kit	
(Thermo	 Fisher	 Scientific)	was	 used	 to	 generate	 a	 standard	 curve	




temperature with solution containing 4% paraformaldehyde and 4% 




NHE9‐GFP,	 primary	 antibodies	 Rab	 5	 (Cell	 Signaling	 Technology),	
Rab	11	(Cell	Signaling	Technology)	and	LBPA	(Echelon)	were	diluted	
1:100 in block solution without Tween 20 and incubated overnight at 
4°C.	Following	PBS	washes,	Alexa	Fluor‐conjugated	secondary	an‐
tibodies (Invitrogen) were used at 1:1000 dilutions for 30 minutes. 
Cells	were	mounted	onto	slides	using	Prolong	gold	antifade	reagent	





2.7 | Inhibition of clathrin‐mediated endocytosis
U251n	 and	 U87	 cells	 were	 pre‐incubated	 in	 the	 presence	 or	 ab‐
sence	of	25	µmol/L	Pitstop‐2	(Sigma)	for	25	minutes	or	80	μmol/L	
of	dynasore	 (Sigma)	 for	30	minutes	 following	previously	published	
protocols 16‐18	before	loading	with	GNP.	For	transferrin	uptake	ex‐
periments, the cells were serum starved for 30 minutes and then 
incubated	with	75	µg/mL	of	Alexa	Fluor	568‐conjugated	transferrin	
for	15	minutes.	For	these	experiments,	Pitstop‐2	was	added	during	
the last 10 minutes of serum starvation and continued during the 
15 minutes of transferrin incubation.
2.8 | NEPTT and cell death analysis
Gold nanoparticles‐loaded cells were irradiated in wells of 96‐well 
plate using a laser (3 W), with beam diameter 2 mm, which was posi‐
tioned seven inches above the well to illuminate the full area of the 
well	of	the	96‐well	plate.	Two	major	processes	by	which	NEPTT	in‐
duces	cell	death	are	apoptosis	and	necrosis.	We	used	Apoptosis	and	
Necrosis	Quantitation	Kit	 Plus	 (Biotium)	 for	 quantifying	 apoptotic	
and	necrotic	cells	using	fluorescence	microscopy.	An	equal	number	
of	cells	plated	on	two	coverslips	were	loaded	with	GNPs.	One	set	of	
cells was irradiated with 808 nm light and the other set of cells not 
subjected to irradiation were used as control. Cell death was assayed 
within an hour after the treatment.
Following	 manufacturer's	 instructions,	 the	 cells	 were	 washed	
twice	with	PBS	followed	by	the	addition	of	two	staining	solutions.	
Annexin	V‐488	 stains	 apoptotic	 cells	 green	 by	 binding	 phosphati‐
dylserine	 (PS)	 on	 the	 cell	 surface	 and	 ethidium	 homodimer‐III	 a	
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A	 second	 approach	 we	 used	 to	 analyse	 apoptosis	 was	 Terminal	
deoxynucleotidyl	 transferase	 (TdT)	 dUTP	Nick‐End	 Labeling	 assay	
(TUNEL).	 This	 was	 conducted	 using	 In	 Situ	 Cell	 Death	 Detection	
(fluorescein) Kit (Roche). The assay was performed according to the 
manufacturer's	 protocol.	 Briefly,	 an	 equal	 number	 of	 GNP‐loaded	
NHE9 overexpressing cells were plated in an 8‐well glass slide 
(Nunc). While the control group was not irradiated, laser treat‐






of the three independent experiments, and the average number of 
TUNEL	positive	cells	was	plotted.
2.9 | Cell proliferation assay
Cells were plated simultaneously in equal numbers and allowed 




number of control and NHE9 overexpressing cells were loaded with 
GNPs	and	subjected	 to	 treatments	as	 indicated	 in	 the	 figure	 leg‐
ends.	Cell	growth	was	monitored	using	 the	CellTiter	96	Aqueous	
One	 Solution	 Cell	 Proliferation	 Assay	 (MTS,	 Promega),	 following	
manufacturer's instructions. Briefly, 48 hours after the indicated 
treatments, 20 μL	of	CellTiter	96	Aqueous	One	Solution	 reagent	
was added to each well of cells in a 96‐well plate and incubated for 
2 hours at 37°C. The absorbance was measured at 490 nm using a 
plate reader.
2.10 | Macrophage migration assay
The	 tumour	 tropic	 ability	 of	 RAW264.7	 cells	 was	 examined	 by	
a transwell migration assay, as described previously.19 Briefly, 
RAW264.7	 cells	 loaded	 with	 or	 without	 GNPs	 were	 suspended	
in serum‐free culture  media and plated in the upper chamber 
of the transwell. The lower chamber of the transwell was filled 
with	 serum‐free	 	 media	 in	 which	 U251	 and	 U87	 cells	 were	 cul‐
tured	for	48	hours	(conditioned	media).	For	negative	control,	the	
lower chamber was filled with culture media without serum. The 
RAW264.7	were	incubated	in	the	transwell	chambers	under	these	
conditions for 6 hours, following which the cells remaining in the 
upper chamber were removed with a cotton swab. The cells that 
migrated to the other side of the transwell were detached and 
total	protein	 levels	were	estimated	using	BCA	assay	kit	 (Thermo	
Fisher).
2.11 | In vitro model of blood‐brain barrier and 
trojan horse delivery of GNPs to glioblastoma cells
Human brain microvascular endothelial cells (hBMVECs) were cul‐
tured	by	seeding	growth		media	containing	7	×	104 cells in the upper 
chamber. Transendothelial electrical resistance (TEER) was moni‐
tored	 using	 EVOM	volt‐ohmmeter	 (World	 Precision	 Instruments).	
The average TEER of the monolayers on day 6 was ~600 Ohm‐cm−2 
and	did	not	change	significantly	thereafter.	U251	or	U87	cells	grown	
to confluence on a coverslip were placed in the lower chamber of 
the 6‐well plate insert (ThinCert, 0.4 micron transparent insert, 
USA	Scientific)	where	hBMVECs	were	cultured	for	5	days.	20	ng/
mL	TNF‐α was also added on day 5 to induce overexpression of cell 




cells on coverslips were washed and incubated with Calcein Blue for 
30 minutes as described above. The mean fluorescence intensity in 
U251	and	U87	cells	was	determined	by	microscopy.
3  | RESULTS
3.1 | NHE9 expression elevates GNP uptake in 
glioblastoma cells
Silica	cores	of	211.15	±	5.5	nm	in	diameter	were	synthesized	as	de‐
scribed in our previously published.21 The surface of the silica core 
was modified by trimethoxysilylpropyl‐modified polyethyleneimine 
(TSPEI).	This	modification	provides	positively	charged	imine	nitrogen	




on the silica core surface, using formic acid, leads to the generation 
of	 gold	nanoparticle	 seeds	 (Figure	1A).	These	 seeds	were	used	as	
nucleation	sites	to	grow	~59	nm	gold	shell	(Figure	1B	and	Table	S1).12 
These	particles	 (silica	 core	with	 gold	 nanoshell,	 Figure	1B)	 are	 re‐
ferred	to	as	gold	nanoparticles	(GNPs)	henceforth.	GNPs	exhibited	a	
broad spectral absorption from the visible to the near‐infrared (NIR) 
region	with	a	peak	centred	around	560	nm.	GNP‐enabled	photother‐
mal therapy is normally induced by irradiation in the NIR region, as 
absorption by biomolecules such as haemoglobin and melanin is re‐
duced within this optical window.22	We	assessed	the	ability	of	GNPs	
to convert light energy from a NIR laser (808 nm) to heat by measur‐
ing temperature change in both water and cell culture media with‐
out	serum	(Figure	1C‐D).	In	both	water	and	the	culture	media	within	
5 minutes of irradiation, a more than 6°C temperature increase was 
observed.
It	is	widely	accepted	that	GNPs	enter	cells	mostly	via	endocytic	
pathways. However, the factors that influence cellular uptake of 
GNPs	are	still	not	completely	clear.	To	determine	the	non‐toxic	dos‐
age	of	GNPs	that	are	in	U251	and	U87	glioblastoma	cells,	we	used	
fluorescence quenching of Calcein Blue molecules.23 Calcein Blue 
AM	is	a	cell‐permeant	esterase	substrate	that	is	weakly	fluorescent	
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outside the cell. Once internalized, it accumulates in endosomal 
compartments	 where	 the	 AM	 esters	 are	 cleaved	 by	 esterases	 to	
yield highly fluorescent molecules. However, near the surface of 
GNPs,	the	fluorescence	signals	are	significantly	quenched.24 The flu‐




for the remaining experiments.
Previous	 studies	 in	 glioblastoma	 cells	 revealed	 a	 general	 in‐
crease in membrane receptors and endocytic uptake upon NHE9 
expression.4,5,10 Hence, we expected glioblastoma cells transduced 
with	NHE9‐GFP	to	have	significantly	higher	GNP	uptake	relative	to	





control cells using inductively coupled plasma mass spectrometry 
(ICP‐MS).	We	observed	~17‐fold	 increase	 in	GNP	uptake	 in	NHE9	
overexpressing	cells	relative	to	control	(Figure	2C).	Consistent	with	
this observation, calcein fluorescence quenching experiments con‐
firmed	the	increase	in	GNP	uptake	with	ectopic	expression	of	NHE9	
in	U251	(Figure	2D‐E)	and	U87	cells	(Figure	2F).	We	did	not	observe	
any significant difference in Calcein Blue fluorescence between con‐
trol and glioblastoma cells overexpressing NHE9, in the absence of 
GNPs.	These	results	clearly	indicate	that	increased	NHE9	expression	
correlates	positively	with	GNP	accumulation	in	glioblastoma	cells.









to	absorbance	of	U251	cells	not	loaded	with	GNPs.	The	error	bars	represent	standard	deviation	(SD)	**P	<	.01	and	*P < .05, significant 
differences	relative	to	control	are	indicated	by	the	asterisks.	NS	indicates	no	significant	difference	relative	to	control.	Statistical	analysis	was	
done	using	Student's	t test. Graphs represent an average of at least three biological replicates
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3.2 | Elevation in uptake of GNPs occurs via 
clathrin‐mediated endocytosis
To	determine	the	mechanism	for	elevated	uptake	of	GNPs	by	glio‐
blastoma cells overexpressing NHE9, the subcellular localization of 
NHE9‐GFP	in	U251	cells	was	examined.	Similar	to	our	previous	ob‐
servations	in	normal	glia	and	U87	cells,5,8 NHE9 localized predomi‐
nantly	to	early	and	recycling	endosomes	in	U251	glioblastoma	cells	
(Figure	3A).	Consistent	with	its	role	in	transporting	protons	out	of	the	
endosome in exchange for sodium or potassium ions, overexpression 
of NHE9 resulted in alkalizing the endosomal lumen by ~1 pH unit 
(Figure	3B).	To	determine	whether	 the	 increased	GNP	uptake	was	
a result of NHE9’s ion exchange activity and not some non‐specific 
effect of NHE9 overexpression, we evaluated the effect of a previ‐
ously	described	loss‐of‐function	mutation	(S438P)	in	NHE9,	on	GNP	
uptake.5 This mutant protein failed to significantly effect endosomal 
pH	(Figure	3C),	despite	localizing	to	sorting	and	recycling	endosomes	
similar to the wild‐type NHE9 (data not shown). Concurrently, no 
increase	 in	GNP	uptake	was	observed	 (Figure	3D).	This	confirmed	
the	increase	in	GNP	uptake	is	due	to	NHE9	overexpression.
Clathrin‐mediated endocytosis (CME) facilitates the internal‐
ization and recycling of receptors engaged in transporting various 
cargos	including	GNPs.	We	hypothesized	that	the	increase	in	GNP	
uptake due to NHE9 overexpression is mediated through CME. 
To test this hypothesis, we evaluated the effect of CME inhibitor 
Pitstop2	 on	 the	 uptake	 of	 GNPs	 in	 NHE9	 overexpressing	 U251	
and	 U87	 glioblastoma	 cells.	 Coated	 pit	 assembly	 and	 dissociation	
required for internalization of plasma membrane receptors is orga‐
nized	by	clathrin	via	 its	terminal	domain.	Pitstop2	has	been	shown	
to selectively block endocytic ligand association with the clathrin 
terminal domain.17	 Incubation	 for	 25	 minutes	 with	 Pitstop2	 re‐













analysis	was	done	using	Student's	t test. Graphs represent an average of at least three biological replicates
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specifically due to CME inhibition, we examined the effect of an‐
other CME inhibitor, dynasore.18,25,26 Treatment with dynasore, a 
cell‐permeable	 inhibitor	 of	 dynamin	 GTPases	 that	 disrupts	 CME,	
also resulted in a significant increase in Calcein Blue fluorescence 
relative	to	untreated	cells	(Figure	4I‐L).	Together,	these	observations	
support the idea that alkalization of endosomal lumen by NHE9 
leads	to	elevated	clathrin‐mediated	endocytic	uptake	of	GNPs.
3.3 | NEPTT induces cell death via apoptosis
NEPTT‐enabled	ablation	of	cancer	cells	depends	on	efficient	thermal	
conversion	of	near‐infrared	light	by	GNPs.	Consistent	with	increased	




laser irradiation alone, no significant differences in cell viability be‐
tween NHE9 overexpressing and control glioblastoma cells were ob‐
served (data not shown). However, photothermal therapy is known 
to induce cell death by apoptosis and necrosis depending on irradia‐
tion parameters.27
Apoptosis	 is	 the	preferred	way	to	 induce	cell	death	as	primary	
necrosis leads to pro‐inflammatory responses. To evaluate the 
type of cell death induced by near‐infrared irradiation (808 nm), we 
conducted	 dual	 staining	 of	 cells	 with	 Annexin	 V	 (stains	 apoptotic	
cells)	and	ethidium	homodimer‐III	 (stains	necrotic	cells;	Figure	5C).	
Quantitative comparison of the staining showed that apoptotic cell 














was	done	using	Student's	t test. Graphs represent an average of at least three biological replicates
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Student's	t test. Graphs represent an average of at least three biological replicates
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NHE9,	after	irradiation.	Together,	this	evidence	confirms	that	NEPTT	
initiates apoptosis to induce cell death, which is higher in glioblas‐
toma cells overexpressing NHE9.
3.4 | Macrophages mediate delivery of GNPs to 
glioblastoma cells across an intact blood‐brain barrier
During the early stages of glioblastoma development, the blood‐
brain	barrier	(BBB)	is	intact	and	prevents	direct	delivery	of	GNPs	
to tumour cells via blood circulation. It's only later when the in‐
tegrity	of	the	BBB	is	compromised	by	the	tumour,	the	GNPs	could	








U251	 conditioned	 media	 (Figure	 6C).	 A	 statistically	 significant	
difference	in	the	migration	ability	between	free	and	GNP‐loaded	
macrophages	 with	 U251	 conditioned	 media	 was	 not	 observed	
(Figure	6C).
With	the	goal	of	assessing	the	transcytosis	efficiency	of	GNP‐
loaded	 macrophages,	 RAW264.7	 cells	 were	 used	 in	 conjunction	
with	 an	 in	 vitro	 model	 of	 BBB	 (Figure	 6D‐E).	 Our	 experimental	




negatively impact treatment success, apoptosis is the preferred mechanism as it does not elicit such responses. Representative micrograph 
of	dual	staining	of	U251	cells	with	Annexin	V	(green,	apoptosis)	and	ethidium	homodimer‐III	(red,	necrosis)	after	NEPTT	is	shown.	Scale	bar	
(white	line)	is	100	µm.	Quantitative	analysis	of	apoptotic	and	necrotic	cell	death	in	U87	(D)	and	U251	(E)	cells	subjected	to	NEPTT.	Annexin	





by	TUNEL	assay,	from	fluorescence	micrographs.	Scale	bar	(white	line)	is	50	µm.	The	error	bars	represent	SD	***P	<	.001	and	**P < .01. 
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design consisted of human brain microvascular endothelial cells 
(hBMVECs) grown as a monolayer on a transwell membrane, with 
U251	cells	plated	in	the	bottom	of	the	transwell	chamber.	The	integ‐
rity of the barrier was assessed by measuring the transendothelial 
electrical resistance (TEER). The TEER plateaued at ~600 Ωcm2 in 
about	6	days	after	plating	(Figure	6E).	To	better	simulate	the	tumour	
microenvironment,	 20	 ng/mL	of	 TNF‐α known to induce overex‐
pression of cell adhesion molecules in endothelial cells of the BBB 















Graphs represent an average of at least three biological replicates
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was added.20	The	transcytosis	ability	of	GNPs	alone	and	loaded	in	
macrophages was compared by monitoring the loss in Calcein Blue 
fluorescence	 of	U251	 cells.	 As	 shown	 in	 Figure	 6F,	macrophage‐
mediated	delivery	of	GNPs	is	twofold	higher	than	GNP	treatment	
alone. These results clearly indicate that macrophages mediated 
delivery	of	our	GNPs.
3.5 | Combinatorial treatment with NEPTT 
increases the efficacy of EGFR inhibitor
To	further	explore	the	therapeutic	potential	of	NEPTT,	we	evaluated	
if a combinatorial approach with erlotinib would more effectively 
inhibit	proliferation	of	tumour	cells	overexpressing	NHE9.	Previous	
studies have shown that NHE9 overexpression exerts post‐transla‐
tional	 control	 by	 increasing	 persistence	 of	 EGFRs	 on	 glioblastoma	
cell membranes, by attenuating receptor turnover significantly.4 
Consistent	 with	 increased	 membrane	 persistence	 of	 EGFRs,	 effi‐
cacy	of	erlotinib,	an	FDA‐approved	receptor	tyrosine	kinase	inhibi‐
tor	of	EGFR,	is	significantly	reduced.	The	IC50 of erlotinib increased 
from	~20	µg/mL	in	control	cells	to	~50	µg/mL	in	U251	cells	overex‐
pressing	NHE9	(Figure	7A).	The	IC50 of erlotinib decreased five fold 
when	 used	 in	 combination	 with	 NEPTT	 (Figure	 7B).	 Results	 from	
similar	experiments	 in	U87	cells	were	consistent	with	what	 results	
in	U251	cells	 (Figure	7C‐D).	Our	data	clearly	demonstrate	a	signifi‐
cant increase in efficacy of erlotinib when used in combination with 
NEPTT.
4  | DISCUSSION
The pathophysiological mechanism underlying the subset of glioblas‐
tomas with NHE9 overexpression (GBM9+) was recently identified.4 
This provided insight into a hitherto unknown link between endo‐
somal pH and gliomagenesis. NHE9 is a master regulator of cargo 
delivery and recycling by mediating inside‐out control of oncogenic 
signalling in glioblastoma.4,8 Increased cell surface receptor densi‐
ties are the hallmark of GBM9+ tumours.4,8 This gain of function ob‐
served in GBM9+ tumours formed the basis for our study directed 
at identifying an effective therapeutic strategy for GBM9+ subset 
of tumours.
Gold nanoparticle uptake by mammalian cells is mediated by ca‐
veolae‐mediated endocytosis, clathrin‐mediated endocytosis and 
micropinocytosis.29 The specific mode utilized for uptake, how‐
ever,	depends	on	GNP	properties	such	as	surface	chemistry,	net	
charge, size, shape and protein corona (protein layer on nanopar‐
ticles due to proteins adsorbed from biological fluids).30	The	GNP	
uptake parts of our experiments were conducted in serum‐free 
media, to avoid the effects of serum proteins and alterations to the 
net	charge	on	GNPs.	We	observed	a	~17‐fold	increase	in	GNP	up‐
take via clathrin‐mediated endocytosis, resulting from a ~10‐fold 
change	in	NHE9	transcript	levels	(Figure	8A‐B).	Exceptionally	high	
transport rates of ~1500 ions per second have been estimated for 
sodium‐proton exchangers.31 Therefore, even small perturbations 
in NHE9 expression could result in big changes in the ionic milieu 
F I G U R E  7  NEEPT	attenuates	






erlotinib and cell viability was measured 
by	MTS	assay.	The	dotted	line	indicates	
the erlotinib concentration (x‐axis) at 
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within the endosomal lumen. However, the specific molecular 
mechanism(s) linking ion exchange activity of NHE9 to endocytic 
trafficking is not completely clear. Recently published work by the 
Brett group suggests that the NHE9 yeast ortholog is important 
for fusion of the endosomes with lysosomes.32 The molecular 
mechanisms facilitating this are evolutionarily conserved. Changes 
in NHE9 expression likely affect pH‐sensitive machinery involved 
in	 SNARE‐mediated	merging	 of	 the	 lipid	 bilayers	 on	 endosomes	
and lysosomes. This fusion is the last step of endocytosis, required 
for surface protein degradation.
Modes of nanoparticle delivery for malignant glioblastomas 
have received much attention during the last few years. In vivo, 
intravenous	injection	of	GNPs	has	better	therapeutic	benefit	than	
direct	infusion	of	GNPs	into	the	tumour.33	GNPs	accumulate	in	tu‐
mours via enhanced permeability and retention effect by passing 
through compromised endothelial tumour vasculature, especially 
during the later stages of the cancer.34	GNPs	directly	infused	into	
the tumour diffuse in the interstitial space around the tumour 
cells without any tumour cell‐specific localization.33 Thus, when 
GNPs	 are	 presented	 to	 glioblastoma	 cells	 via	 an	 intravenous	 in‐
jection, GBM9+ tumour cells could potentially outcompete sur‐
rounding normal cells due to both increased endocytic uptake and 
enhanced permeability and retention. This could have potentially 
far‐reaching effects not only in terms of treatment effectiveness 
but also protecting cells from hyperthermia. However, during 
early stages of glioblastoma, the BBB is still intact impeding the 
GNPs	 from	 entering	 the	 tumour.	 Even	 in	 later	 stages,	 increased	
interstitial fluid pressure inside the tumour and the blood tumour 
barriers	 need	 to	 be	 overcome	 for	 the	 GNPs	 to	 efficiently	 enter	
the tumour cells. This report looked at the feasibility of delivering 
F I G U R E  8  Schematic	illustrating	NHE9	overexpression	in	glioblastoma	(GBM)	enhances	NEPTT.	NHE9	is	localized	predominantly	
to early and recycling endosomes in GBM cells. Overexpression of NHE9 results in alkalizing the endosomal lumen to affect clathrin‐
mediated endocytosis (CME). CME facilitates the internalization and recycling of receptors. Endosomal alkalization resulting from NHE9 
overexpression	has	also	been	shown	to	divert	trafficking	of	receptors	away	from	lysosome.	A	combination	of	increased	internalization	
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the	GNPs	we	synthesized,	to	GBM9+	tumour	cells	across	the	BBB.	
Cell‐based carriers have been exploited in recent years as Trojan 
horses	to	carry	GNPs	through	barriers	into	brain	tumour	sites.19,35 
Macrophages are a class of white blood cells that can naturally 
infiltrate most solid tumours including glioblastomas.19,36,37 On 
the	endothelial	cells	of	the	BBB,	cell	adhesion	molecules	 (CAMs)	
overexpressed as result of the tumour inflammation mediate in‐
teraction between macrophages and the endothelial cells to fa‐
cilitate migration across the barrier.20 We demonstrate migration 
of	GNP‐loaded	macrophages	and	delivery	to	GBM9+	tumour	cells	
across the BBB using a transwell monolayer model. Direct contact 
between	macrophages	 and	GBM9+	 tumour	 cells	 facilitates	GNP	
delivery. In vivo, tumour inflammation environment could facili‐
tate delivery via exocytosis.19
In conclusion, while NHE9 overexpression enables the oncogenic 




ness, spatiotemporal manipulation of photothermal treatment and 
encapsulation of erlotinib in the nanoparticles. Encapsulation effi‐
ciently reduces drug‐induced toxicity to other cells and could also 
improve	the	amount	of	drug	reaching	the	tumour	cells.	Future	stud‐
ies will focus on evaluating these findings in nude mice with intracra‐
nial GBM9+ tumours.
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